Somatic mutations in cancer genomes are accumulated by various mutational processes (Greenman et al., 2007; Stratton et al., 2009), such as intrinsic DNA repair defects (Rosenthal et al., 2016) or extrinsic exposure to carcinogens (Alexandrov et al., 2016). Mutational processes leave characteristic mutation patterns in the genome, known as mutational signatures (Alexandrov et al., 2020; Alexandrov et al., 2013). While genomic studies have extensively characterized these signatures (Alexandrov et al., 2016; Burns et al., 2013; Pfeifer et al., 2005; Roberts et al., 2013), their impact on the proteome remains largely unexplored. Our lab recently uncovered that certain mutational processes predominantly induce nonsense mutations in hallmark cancer genes and pathways, leading to protein truncation and loss-of-function effects (Adler et al., 2023). Here, we have conducted a proteogenomic analysis to delineate the impact of over 700,000 missense variants (causing amino acid substitutions), collected from 12,000 genomes spanning 24 cancer types from TCGA (Weinstein et al., 2013), on protein interaction networks. We mapped the variants to 150,000 experimentally validated phosphorylation sites in the proteome, catalogued by ActiveDriverDB (Krassowski et al., 2018) and applied MIMP (Wagih et al., 2015), a machine learning model, to predict their potential to rewire phosphorylation sites. Specific single-base substitution (SBS) signatures were revealed to selectively alter phosphorylation-associated conserved, short linear protein motifs, i.e., SliMs (Davey et al., 2012). UV signature SBS7b was found to disrupt CDK kinase-substrate interactions regulating cell cycle and proliferation in melanoma. APOBEC-driven DNA editing signature SBS2 impacted CK2 kinase-associated motifs in lung cancers, leading to tumor progression. Hallmark cancer genes like BRAF in melanoma and U2AF1 in lung adenocarcinoma were identified to be hotspots for these kinase motif-altering variants, arising from distinct signatures. In BRAF, V600E substitutions primarily triggered by ageing-correlated SBS5 and UV-linked SBS7b signatures, induces a new phosphorylation site recognised by the family of Polo-Like Kinases (PLK). This putatively explains why elevated expression levels of PLK kinases in patients with the BRAF-V600E substitution are associated with resistance to vemurafenib treatment (Babagana et al., 2020) and significantly worse overall survival rates (Uebel et al., 2023). Thus, studying how mutational processes rewire the protein interactome provides vital insights into how endogenous factors and lifestyle variables, such as tobacco consumption and sunscreen negligence, reconfigure signaling events in cancer. These alterations profoundly impact cancer risk, progression, and tumor heterogeneity. Moreover, our study holds promise to identify therapeutic targets and biomarkers, advancing precision oncology.